Toronto Dominion Bank
VTGN icon

Toronto Dominion Bank’s VistaGen Therapeutics VTGN Stock Holding History

Toronto Dominion Bank’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-46
Closed -$241 – 1818
2023
Q3 		$241 Buy
+46
New +$204 ﹤0.01% 1578

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Toronto Dominion Bank's VTGN Position: Q4 2023 in Review

Toronto Dominion Bank sold out of VistaGen Therapeutics (VTGN) in Q4 2023, closing a stake of 46 shares — an estimated $241 sold.

Toronto Dominion Bank first reported a position in VTGN in Q3 2023 and held it in 1 quarter. The position peaked at $241 in Q3 2023. 46 funds tracked by Wall St. Rank hold VTGN as of Q4 2023.

  • Toronto Dominion Bank reported no remaining VistaGen Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Toronto Dominion Bank sold 46 VistaGen Therapeutics shares in Q4 2023, an estimated $241.
  • Toronto Dominion Bank first reported a position in VistaGen Therapeutics in Q3 2023 and held it in 1 quarter.
  • Toronto Dominion Bank's VistaGen Therapeutics position peaked at $241 in Q3 2023.
  • 46 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2023.

Based on Toronto Dominion Bank's 13F filing for Q4 2023, filed 13 Feb 2024.